The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2019 | Ublituximab, umbralisib and ibrutinib in CLL and NHL
The combination of ublituximab, umbralisib and ibrutinib was investigated in an open-label, Phase I dose escalation and expansion trial in chronic lymphocytic leukemia or R/R B-cell non-Hodgkin lymphoma (NCT02006485). We spoke to Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, about the results seen with this chemo-free triplet regimen. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
